Press releases

Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, today announced that the United States Food and Drug Administration (FDA) has provided positive feedback regarding the continued development of the company's leading drug candidate RMC-035 in open-heart surgery. The next developmental step includes a phase...

Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.

Guard Therapeutics (GUARD), a biotechnology company specializing in kidney diseases, today announced that its late breaking clinical trial abstract has been selected for presentation at the American Society of Nephrology (ASN) Kidney Week in Philadelphia, Pennsylvania, in November 2023. The abstract includes results from the Phase 2 clinical...

Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, today announced further information regarding the development strategy for the investigational drug RMC-035. An advisory meeting with the U.S. Food and Drug Administration (FDA) will be requested to explore dose optimization and the framework for a future...

Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, today announced top-line results from its Phase 2 clinical study AKITA, evaluating RMC-035 for the prevention of kidney injury in open-heart surgery. In line with previous communication patient recruitment was prematurely stopped, and as expected the primary...